Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Single-cell transcriptomics reveals gene expression heterogeneity but suffers from stochastic
dropout and characteristic bimodal expression distributions in which expression is either …

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

Background Observational data and non-human primate challenge studies suggest that cell-mediated
immune responses might provide control of HIV replication. The Step Study …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …

Background In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma
viraemia after infection, and HIV-1 incidence was higher in vaccine-treated than in placebo-…

For more than two decades, HIV has infected millions of people worldwide each year through
mucosal transmission. Our knowledge of how HIV secures a foothold at both the molecular …

Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime–…